Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiotensins
Studies from Technical University in the area of angiotensins described
July 8th, 2009
"CYT-006-AngQb, under development by Cytos Biotechnology AG, is a vaccine in which a peptide derived from the angiotensin II molecule is conjugated to the surface of the highly repetitive structure of virus-like particles. CYT-006-AngQb was designed to treat hypertension with the benefit of relatively long-lasting effects that do not require daily dosing," scientists writing in the journal Current Opinion in Investigational Drugs report. "In spontaneously hypertensive rat models, CYT-006-AngQb induced strong angiotensin-II-specific antibodies and reduced systolic blood pressure. In a phase I clinical trial, single doses of CYT-006-AngQb were well tolerated in...
Source: Vaccine Weekly (2009-07-08)
|
